Investigating the effect of nandrolone on the quality of life

Investigating the effect of nandrolone on the quality of life in female patients with heart failure

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231116060079N1

Enrollment

Registered

2023-12-30

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Heart failure

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive nandrolone decanoate 25 mg intramuscularly once a week for one month that will be provided by Caspian Pharmaceutical

Eligibility

Sex/Gender

Female

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Women with heart failure FCII and FCIII Ejection Fraction less than and equal to 40 Age over 50 years

Exclusion criteria

Exclusion criteria: Occurrence of ischemia in the last 6 months of the disease Hormonal disorders Consumption of oral contraceptive pill (OCP) Hypertension

Design outcomes

Primary

Measure	Time frame
Quality of Life. Timepoint: Before and six weeks after the intervention. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Cardiac ejection fraction. Timepoint: Before and six weeks after the intervention. Method of measurement: Eco-cardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mahammadreza Taban Sadeghi

Tabriz University of Medical Sciences

taban@tbzmed.ac.ir+98 41 3337 3900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026